Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy

Trial ID or NCT#

NCT01449279

Status

not recruiting iconNOT RECRUITING

Purpose

To determine the safety of local palliative radiation therapy used in combination with anti-CTLA-4 immunotherapy.

Official Title

A Pilot Study of Ipilimumab in Subjects With Stage IV Melanoma Receiving Palliative Radiation Therapy

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Susan Knox

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061

View on ClinicalTrials.gov